Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD | P32754 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CTSV | O60911 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MGMT | P16455 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16266200 | 0.85 | MGMT (0.51) | HPDCTSVCTSLMAPTCYP19A1 | |
| SCHEMBL2991148 | 0.83 | HTT (0.53) | HPDHTTALDH1A1CTSVCTSL | |
| SCHEMBL2434879 | 0.81 | CYP19A1 (0.51) | HPDCTSVCTSLMAPTCYP19A1 | |
| SCHEMBL21685240 | 0.80 | MGMT (0.53) | HPDCTSVCTSLMAPTCYP19A1 | |
| SCHEMBL19320318 | 0.79 | CYP19A1 (0.49) | HPDTDP1MAPTCYP19A1MGMT | |
| SCHEMBL34476061 | 0.79 | CYP19A1 (0.46) | HPDCTSVCTSLMAPTCYP19A1 | |
| SCHEMBL2432724 | 0.79 | CYP19A1 (0.49) | HPDHTTALDH1A1CTSVCTSL | |
| SCHEMBL1202073 | 0.79 | RAB9A (0.53) | ALDH1A1CTSVCTSLRAB9ATDP1 | |
| SCHEMBL6133440 | 0.78 | FFAR4 (0.58) | HTTALDH1A1RAB9ATDP1MAPT | |
| SCHEMBL1646547 | 0.78 | HTT (0.57) | HTTALDH1A1TDP1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130279-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | NESTEC S.A. (CH) | 2016-05-12 | — | — | US | disclosed |
| US-20160130279-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | NESTEC S.A. (CH) | 2016-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130279-A1 | PATHWAY SPECIFIC ASSAYS FOR PREDICTING IRRITABLE BOWEL SYNDROME DIAGNOSIS | FABP2, TPH2, TPH1 | HPD 243/4885HTT 4478/4885ALDH1A1 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.